Fig. 4
From: In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
In vivo evaluation of ABCB1 overexpression effects on bosutinib activity. a–c Tumor-size measurements in mice injected with K562S (a), K562DOX (b), or K562DOX/sh P-GP (c). The treatment length with bosutinib (BOS) is indicated. d Proliferation experiment on ex vivo cells derived from K562S, K562DOX, and K562DOX/sh P-GP tumors. Cells were treated with increasing concentrations of bosutinib for 72 h. Results are the mean of two independent experiments. p values were calculated, comparing each cell line with the following corresponding tumor-derived cells: K562S versus K562S tum (p = 0.38), K562DOX versus K562DOXtum (p = 0.583), and K562DOX/sh P-GP versus K562DOX/sh P-GP tum (p = 0.003)